FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3143063650> ?p ?o ?g. }

• W3143063650 endingPage "503" @default.
• W3143063650 startingPage "503" @default.
• W3143063650 abstract "Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques; however, its use requires site-specific accumulation in the vessels involved in the formation of the plaques to avoid the systemic effects resulting from its indiscriminate biodistribution. In this work, a stable pharmaceutical formulation for Rapa was realized as a dried powder to be dispersed extemporaneously before administration. The latter was constituted by mannitol (Man) as an excipient and a Rapa-loaded polymeric nanoparticle carrier. These nanoparticles were obtained by nanoprecipitation and using as a starting polymeric material a polycaprolactone (PCL)/α,β-poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA) graft copolymer. To obtain nanoparticles targeted to macrophages, an oxidized phospholipid with a high affinity for the CD36 receptor of macrophages, the 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdia-PC), was added to the starting organic phase. The chemical–physical and technological characterization of the obtained nanoparticles demonstrated that: both the drug loading (DL%) and the entrapment efficiency (EE%) entrapped drug are high; the entrapped drug is in the amorphous state, protected from degradation and slowly released from the polymeric matrix; and the KOdia-PC is on the nanoparticle surface (KP-Nano). The biological characterization demonstrated that both systems are quickly internalized by macrophages while maintaining the activity of the drug. In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug." @default.
• W3143063650 created "2021-04-13" @default.
• W3143063650 creator A5005052674 @default.
• W3143063650 creator A5015600854 @default.
• W3143063650 creator A5052146687 @default.
• W3143063650 creator A5065727177 @default.
• W3143063650 creator A5070682509 @default.
• W3143063650 creator A5082819674 @default.
• W3143063650 creator A5088767916 @default.
• W3143063650 date "2021-04-07" @default.
• W3143063650 modified "2023-09-30" @default.
• W3143063650 title "Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis" @default.
• W3143063650 cites W1509292905 @default.
• W3143063650 cites W1941499335 @default.
• W3143063650 cites W1949072443 @default.
• W3143063650 cites W1970637701 @default.
• W3143063650 cites W1978029175 @default.
• W3143063650 cites W1981894952 @default.
• W3143063650 cites W1997780934 @default.
• W3143063650 cites W2001464259 @default.
• W3143063650 cites W2033854654 @default.
• W3143063650 cites W2055348159 @default.
• W3143063650 cites W2123600477 @default.
• W3143063650 cites W2127063807 @default.
• W3143063650 cites W2143463421 @default.
• W3143063650 cites W2168897708 @default.
• W3143063650 cites W2312654759 @default.
• W3143063650 cites W2320404255 @default.
• W3143063650 cites W2396433385 @default.
• W3143063650 cites W2411166269 @default.
• W3143063650 cites W2520674072 @default.
• W3143063650 cites W2525631789 @default.
• W3143063650 cites W2602684234 @default.
• W3143063650 cites W2605487049 @default.
• W3143063650 cites W2736841273 @default.
• W3143063650 cites W2739963945 @default.
• W3143063650 cites W2771391703 @default.
• W3143063650 cites W2772657408 @default.
• W3143063650 cites W2791079513 @default.
• W3143063650 cites W2792018411 @default.
• W3143063650 cites W2803821641 @default.
• W3143063650 cites W2809632591 @default.
• W3143063650 cites W2889376614 @default.
• W3143063650 cites W2889521195 @default.
• W3143063650 cites W2890644970 @default.
• W3143063650 cites W2898633878 @default.
• W3143063650 cites W2910266901 @default.
• W3143063650 cites W2915113556 @default.
• W3143063650 cites W2928482340 @default.
• W3143063650 cites W2942187120 @default.
• W3143063650 cites W2981355611 @default.
• W3143063650 cites W2993752356 @default.
• W3143063650 cites W3000608421 @default.
• W3143063650 cites W3026884655 @default.
• W3143063650 cites W3032171212 @default.
• W3143063650 cites W3128238305 @default.
• W3143063650 cites W825658476 @default.
• W3143063650 doi "https://doi.org/10.3390/pharmaceutics13040503" @default.
• W3143063650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8067637" @default.
• W3143063650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33916918" @default.
• W3143063650 hasPublicationYear "2021" @default.
• W3143063650 type Work @default.
• W3143063650 sameAs 3143063650 @default.
• W3143063650 citedByCount "9" @default.
• W3143063650 countsByYear W31430636502021 @default.
• W3143063650 countsByYear W31430636502022 @default.
• W3143063650 countsByYear W31430636502023 @default.
• W3143063650 crossrefType "journal-article" @default.
• W3143063650 hasAuthorship W3143063650A5005052674 @default.
• W3143063650 hasAuthorship W3143063650A5015600854 @default.
• W3143063650 hasAuthorship W3143063650A5052146687 @default.
• W3143063650 hasAuthorship W3143063650A5065727177 @default.
• W3143063650 hasAuthorship W3143063650A5070682509 @default.
• W3143063650 hasAuthorship W3143063650A5082819674 @default.
• W3143063650 hasAuthorship W3143063650A5088767916 @default.
• W3143063650 hasBestOaLocation W31430636501 @default.
• W3143063650 hasConcept C12554922 @default.
• W3143063650 hasConcept C13245373 @default.
• W3143063650 hasConcept C155672457 @default.
• W3143063650 hasConcept C171250308 @default.
• W3143063650 hasConcept C178790620 @default.
• W3143063650 hasConcept C18150654 @default.
• W3143063650 hasConcept C185592680 @default.
• W3143063650 hasConcept C192562407 @default.
• W3143063650 hasConcept C202751555 @default.
• W3143063650 hasConcept C2777807558 @default.
• W3143063650 hasConcept C2779868350 @default.
• W3143063650 hasConcept C2780035454 @default.
• W3143063650 hasConcept C521977710 @default.
• W3143063650 hasConcept C55493867 @default.
• W3143063650 hasConcept C71924100 @default.
• W3143063650 hasConcept C86803240 @default.
• W3143063650 hasConcept C98274493 @default.
• W3143063650 hasConceptScore W3143063650C12554922 @default.
• W3143063650 hasConceptScore W3143063650C13245373 @default.
• W3143063650 hasConceptScore W3143063650C155672457 @default.
• W3143063650 hasConceptScore W3143063650C171250308 @default.
• W3143063650 hasConceptScore W3143063650C178790620 @default.

• next